BDX
AI Execution Plan
BD receives FDA 510(k) clearance for EnCor EnCompass breast biopsy system; $110M investment to expand US prefillable syringe production for biologics; Q4 2025 EPS $3.96 beat estimates; Next earnings ~Feb 4, 2026 with FY26 EPS growth est. +3.1%; Recent outperformance vs peers.
RSI(14): ~70 (Buy zone); MACD: Positive ~1.35; Above key MAs (support ~$200, resistance ~$208); Oscillators lean Buy, overall Neutral-Buy; Low volatility (Beta 0.26).
3-Month AI Outlook
Positive catalysts from FDA approvals, production expansion, & earnings growth; Analyst consensus Buy (avg target ~$206); Potential to $215+ on medtech demand, monitor tariffs & Q1 results.
Option Chain
| Strike | Bid | Ask | IV % | Vol | OI | Time |
|---|
| Strike | Bid | Ask | IV % | Vol | OI | Time |
|---|
Earnings History: BDX
Strategy Overview
Jason Wheel is a systematic, AI‑enhanced trading framework built on probability theory and volatility‑based edge extraction. Designed for the US options market, the system focuses on constructing high‑probability Credit Spread strategies that capture Theta decay while maintaining strict quantitative risk controls to mitigate tail events and support long‑term, stable capital growth.
Rather than relying on directional speculation, the system operates as a closed‑loop asset engine integrating: Macro Risk Control, Multi-dimensional Quantitative Screening, AI-Assisted Decision Making, and Dynamic Position Management.
This architecture enables consistent, rules‑driven execution with an emphasis on risk‑adjusted returns.
Connect with Jason
- Substack: jasonwheel.substack.com
- Email: [email protected]